Notably, FLT3 (FMS-like tyrosine kinase 3) pathway inhibitors, such as G749, could downregulate ANXA9 expression by inhibiting ZMYM2, potentially overcoming treatment failure in CRC patients. This evidence concerns the gene FLT3 and colorectal carcinoma.